TITE-STEIN: Time-to-event simple toxicity and efficacy interval design to accelerate phase I/II trials.

Oncology dose-finding trials are shifting from identifying the maximum-tolerated dose (MTD) to determining the optimal biological dose (OBD), driven by the need for efficient methods that consider both toxicity and efficacy. This is particularly impo…

Preview only. Read the full abstract at the source